Literature DB >> 23820740

N-linked glycosylation of cortical N-methyl-D-aspartate and kainate receptor subunits in schizophrenia.

Janusz Tucholski1, Micah S Simmons, Anita L Pinner, Laurence D McMillan, Vahram Haroutunian, James H Meador-Woodruff.   

Abstract

Dysfunctional glutamate neurotransmission has been implicated in the pathophysiology of schizophrenia. Abnormal expressions in schizophrenia of ionotropic glutamate receptors (iGluRs) and the proteins that regulate their trafficking have been found to be region and subunit specific in brain, suggesting that abnormal trafficking of iGluRs may contribute toward altered glutamatergic neurotransmission. The post-translational modification N-glycosylation of iGluR subunits can be used as a proxy for their intracellular localization. Receptor complexes assemble in the lumen of the endoplasmic reticulum, where N-glycosylation begins with the addition of N-linked oligomannose glycans, and is subsequently trimmed and replaced by more elaborate glycans while trafficking through the Golgi apparatus. Previously, we found abnormalities in N-glycosylation of the GluR2 AMPA receptor subunit in schizophrenia. Here, we investigated N-glycosylation of N-methyl-D-aspartate and kainate (KA) receptor subunits in the dorsolateral prefrontal cortex from patients with schizophrenia and a comparison group. We used enzymatic deglycosylation with two glycosidases: endoglycosidase H (Endo H), which removes immature high mannose-containing sugars, and peptide-N-glycosidase F (PNGase F), which removes all N-linked sugars. The NR1, NR2A, NR2B, GluR6, and KA2 subunits were all sensitive to treatment with Endo H and PNGase F. The GluR6 KA receptor subunit was significantly more sensitive to Endo H-mediated deglycosylation in schizophrenia, suggesting a larger molecular mass of N-linked high mannose and/or hybrid sugars on GluR6. This finding, taken with our previous work, suggests that a cellular mechanism underlying abnormal glutamate neurotransmission in schizophrenia may involve abnormal trafficking of both AMPA and KA receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23820740      PMCID: PMC3919653          DOI: 10.1097/WNR.0b013e328363bd8a

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

Review 1.  Roles and rules of kainate receptors in synaptic transmission.

Authors:  Juan Lerma
Journal:  Nat Rev Neurosci       Date:  2003-06       Impact factor: 34.870

2.  Identification of an endoplasmic reticulum-retention motif in an intracellular loop of the kainate receptor subunit KA2.

Authors:  Yukiko Nasu-Nishimura; David Hurtado; Stephanie Braud; Tina Tze-Tsang Tang; John T R Isaac; Katherine W Roche
Journal:  J Neurosci       Date:  2006-06-28       Impact factor: 6.167

Review 3.  Kainate receptors.

Authors:  Paulo Pinheiro; Christophe Mulle
Journal:  Cell Tissue Res       Date:  2006-07-18       Impact factor: 5.249

4.  Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia.

Authors:  Monica Beneyto; James H Meador-Woodruff
Journal:  Synapse       Date:  2006-12-15       Impact factor: 2.562

5.  Differential regulation of kainate receptor trafficking by phosphorylation of distinct sites on GluR6.

Authors:  Yukiko Nasu-Nishimura; Howard Jaffe; John T R Isaac; Katherine W Roche
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

6.  A defect in the ionotropic glutamate receptor 6 gene (GRIK2) is associated with autosomal recessive mental retardation.

Authors:  Mohammad Mahdi Motazacker; Benjamin Rainer Rost; Tim Hucho; Masoud Garshasbi; Kimia Kahrizi; Reinhard Ullmann; Seyedeh Sedigheh Abedini; Sahar Esmaeeli Nieh; Saeid Hosseini Amini; Chandan Goswami; Andreas Tzschach; Lars Riff Jensen; Dietmar Schmitz; Hans Hilger Ropers; Hossein Najmabadi; Andreas Walter Kuss
Journal:  Am J Hum Genet       Date:  2007-08-31       Impact factor: 11.025

7.  Distinct roles for the kainate receptor subunits GluR5 and GluR6 in kainate-induced hippocampal gamma oscillations.

Authors:  André Fisahn; Anis Contractor; Roger D Traub; Eberhard H Buhl; Stephen F Heinemann; Chris J McBain
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.167

8.  Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia.

Authors:  L V Kristiansen; M Beneyto; V Haroutunian; J H Meador-Woodruff
Journal:  Mol Psychiatry       Date:  2006-05-16       Impact factor: 15.992

9.  Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia.

Authors:  Deborah Bauer; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2009-08-27       Impact factor: 4.939

10.  Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia.

Authors:  Adam J Funk; Gavin Rumbaugh; Vahram Harotunian; Robert E McCullumsmith; James H Meador-Woodruff
Journal:  Neuroreport       Date:  2009-07-15       Impact factor: 1.837

View more
  21 in total

1.  Decreased protein S-palmitoylation in dorsolateral prefrontal cortex in schizophrenia.

Authors:  Anita L Pinner; Janusz Tucholski; Vahram Haroutunian; Robert E McCullumsmith; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2016-02-11       Impact factor: 4.939

2.  Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia.

Authors:  Toni M Mueller; Stefani D Yates; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2016-10-20       Impact factor: 4.939

3.  Loss of α1,6-Fucosyltransferase Decreases Hippocampal Long Term Potentiation: IMPLICATIONS FOR CORE FUCOSYLATION IN THE REGULATION OF AMPA RECEPTOR HETEROMERIZATION AND CELLULAR SIGNALING.

Authors:  Wei Gu; Tomohiko Fukuda; Tomoya Isaji; Qinglei Hang; Ho-hsun Lee; Seiichiro Sakai; Jyoji Morise; Junya Mitoma; Hideyoshi Higashi; Naoyuki Taniguchi; Hiromu Yawo; Shogo Oka; Jianguo Gu
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

4.  Abnormal expression of ER quality control and ER associated degradation proteins in the dorsolateral prefrontal cortex in schizophrenia.

Authors:  Pitna Kim; Madeline R Scott; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2018-02-26       Impact factor: 4.939

5.  Dysregulation of the unfolded protein response (UPR) in the dorsolateral prefrontal cortex in elderly patients with schizophrenia.

Authors:  Pitna Kim; Madeline R Scott; James H Meador-Woodruff
Journal:  Mol Psychiatry       Date:  2019-10-02       Impact factor: 15.992

Review 6.  Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies.

Authors:  Sarah E Williams; Robert G Mealer; Edward M Scolnick; Jordan W Smoller; Richard D Cummings
Journal:  Mol Psychiatry       Date:  2020-05-13       Impact factor: 15.992

7.  Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia.

Authors:  Jordyn M Kippe; Toni M Mueller; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2015-06-20       Impact factor: 4.939

8.  Unconventional secretory processing diversifies neuronal ion channel properties.

Authors:  Cyril Hanus; Helene Geptin; Georgi Tushev; Sakshi Garg; Beatriz Alvarez-Castelao; Sivakumar Sambandan; Lisa Kochen; Anne-Sophie Hafner; Julian D Langer; Erin M Schuman
Journal:  Elife       Date:  2016-09-28       Impact factor: 8.140

9.  N-Glycosylation of GABAA receptor subunits is altered in Schizophrenia.

Authors:  Toni Marie Mueller; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-08-06       Impact factor: 7.853

10.  Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.

Authors:  Radhika Chadha; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2020-01-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.